<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03845387</url>
  </required_header>
  <id_info>
    <org_study_id>KDT1201</org_study_id>
    <nct_id>NCT03845387</nct_id>
  </id_info>
  <brief_title>A Clinical Study of KDT-3594 in Patients With Early Parkinson's Disease.</brief_title>
  <official_title>A Phase II Clinical Study of KDT-3594 in Patients With Early Parkinson's Disease.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kissei Pharmaceutical Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Kissei Pharmaceutical Co., Ltd.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Objective of this study is to investigate the efficacy, safety and pharmacokinetics of
      KDT-3594 in patients with early Parkinson's disease without a concomitant medication of
      L-dopa.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">February 26, 2019</start_date>
  <completion_date type="Anticipated">June 2020</completion_date>
  <primary_completion_date type="Anticipated">June 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Movement Disorder Society-Unified Parkinson's Disease Rating Scale (MDS-UPDRS) score</measure>
    <time_frame>12 weeks</time_frame>
    <description>Change from baseline (Week 0) in MDS-UPDRS total score</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Parkinson's Disease Questionnaire-39 (PDQ-39) score</measure>
    <time_frame>12 weeks</time_frame>
    <description>Change from baseline (Week 0) in PDQ-39 summary index score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Parkinson's Disease Sleep Scale-2 (PDSS-2) score</measure>
    <time_frame>12 weeks</time_frame>
    <description>Change from baseline (Week 0) in PDSS-2 total score</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Parkinson Disease</condition>
  <arm_group>
    <arm_group_label>KDT-3594</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Pramipexole</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Reference drug</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>KDT-3594</intervention_name>
    <description>oral administration, dose titration</description>
    <arm_group_label>KDT-3594</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pramipexole</intervention_name>
    <description>ER formulation, oral administration, dose titration</description>
    <arm_group_label>Pramipexole</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Japanese patients

          -  Patients who are diagnosed with Parkinson's disease according to UK Parkinson's
             Disease society brain bank clinical diagnostic criteria

          -  Patients with Parkinson's disease in Stages 1 to 3 on the Modified Hoehn and Yahr
             Scale

        Exclusion Criteria:

          -  Patients who are suspected any parkinsonism except for idiopathic Parkinson's disease

          -  Patients who underwent neurosurgical treatment (stereotaxic destruction, deep brain
             stimulation etc.) for PD, or patients for whom surgical treatment is scheduled during
             the study

          -  Patients with a complication of obvious dementia, or patients with Mini-Mental State
             Examination (MMSE) score &lt; 24 points
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>79 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nobuo Kanai</last_name>
    <role>Study Director</role>
    <affiliation>Kissei Pharmaceutical Co., Ltd.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Multiple Locations</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>February 15, 2019</study_first_submitted>
  <study_first_submitted_qc>February 15, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">February 19, 2019</study_first_posted>
  <last_update_submitted>March 26, 2020</last_update_submitted>
  <last_update_submitted_qc>March 26, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 30, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Parkinson Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pramipexole</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

